• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

快速且经济高效地检测一大串连续肺癌中的重排。

Rapid and Cost-Efficient Detection of Rearrangements in a Large Consecutive Series of Lung Carcinomas.

机构信息

Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 St.-Petersburg, Russia.

Department of Medical Genetics, St.-Petersburg Pediatric Medical University, 194100 St.-Petersburg, Russia.

出版信息

Int J Mol Sci. 2023 Jun 23;24(13):10530. doi: 10.3390/ijms241310530.

DOI:10.3390/ijms241310530
PMID:37445709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10342123/
Abstract

-kinase-activating gene rearrangements occur in approximately 1-2% of non-small-cell lung carcinomas (NSCLCs). Their reliable detection requires next-generation sequencing (NGS), while conventional methods, such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) or variant-specific PCR, have significant limitations. We developed an assay that compares the level of RNA transcripts corresponding to 5'- and 3'-end portions of the gene; this test relies on the fact that translocations result in the upregulation of the kinase domain of the gene and, therefore, the 5'/3'-end expression imbalance. The present study included 16,106 consecutive NSCLC patients, 14,449 (89.7%) of whom passed cDNA quality control. The 5'/3'-end unbalanced expression was observed in 184 (1.3%) tumors, 169 of which had a sufficient amount of material for the identification of translocation variants. Variant-specific PCR revealed rearrangements in 155/169 (91.7%) tumors. RNA quality was sufficient for RNA-based NGS in 10 cases, 8 of which carried exceptionally rare or novel ( and ) translocations. We also applied variant-specific PCR for eight common rearrangements in 4680 tumors, which emerged negative upon the 5'/3'-end unbalanced expression test; 33 (0.7%) of these NSCLCs showed fusion. While the combination of the analysis of 5'/3'-end expression imbalance and variant-specific PCR allowed identification of translocations in approximately 2% of consecutive NSCLCs, this estimate approached 120/2361 (5.1%) in /////-negative carcinomas. -rearranged tumors obtained from females, but not males, had a decreased level of expression of thymidylate synthase ( < 0.00001), which is a known predictive marker of the efficacy of pemetrexed. The results of our study provide a viable alternative for testing in facilities that do not have access to NGS due to cost or technical limitations.

摘要

激酶激活基因重排在非小细胞肺癌(NSCLC)中约占 1-2%。其可靠检测需要下一代测序(NGS),而传统方法,如免疫组织化学(IHC)、荧光原位杂交(FISH)或变体特异性 PCR,具有显著的局限性。我们开发了一种比较基因 5'和 3'端 RNA 转录本水平的检测方法;该检测方法依赖于以下事实:易位导致基因激酶结构域的上调,因此 5'/3'端表达失衡。本研究纳入了 16106 例连续 NSCLC 患者,其中 14449 例(89.7%)通过了 cDNA 质量控制。在 184 例(1.3%)肿瘤中观察到 5'/3'端不平衡表达,其中 169 例有足够的材料用于鉴定易位变体。变体特异性 PCR 在 155/169 例(91.7%)肿瘤中发现了 易位。在 10 例肿瘤中 RNA 质量足以进行基于 RNA 的 NGS,其中 8 例携带异常罕见或新型(和)易位。我们还在 4680 例肿瘤中应用变体特异性 PCR 检测 8 种常见的 易位,这些肿瘤在 5'/3'端不平衡表达检测中呈阴性;其中 33 例(0.7%)非小细胞肺癌显示出 融合。虽然 5'/3'端 表达失衡分析与变体特异性 PCR 的结合可在大约 2%的连续 NSCLC 中鉴定出 易位,但在 /////-阴性癌中,这一估计值接近 120/2361(5.1%)。从女性而非男性获得的 易位肿瘤的胸苷酸合成酶表达水平降低(<0.00001),这是培美曲塞疗效的已知预测标志物。我们的研究结果为那些由于成本或技术限制而无法进行 NGS 的机构提供了一种可行的替代 检测方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a151/10342123/5dfb10edcc96/ijms-24-10530-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a151/10342123/cfe4104f52d0/ijms-24-10530-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a151/10342123/5dfb10edcc96/ijms-24-10530-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a151/10342123/cfe4104f52d0/ijms-24-10530-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a151/10342123/5dfb10edcc96/ijms-24-10530-g002.jpg

相似文献

1
Rapid and Cost-Efficient Detection of Rearrangements in a Large Consecutive Series of Lung Carcinomas.快速且经济高效地检测一大串连续肺癌中的重排。
Int J Mol Sci. 2023 Jun 23;24(13):10530. doi: 10.3390/ijms241310530.
2
Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.全面评估 5'-/3'-端 mRNA 不平衡表达检测作为肺癌中 ALK 和 ROS1 融合的筛查工具。
Cancer Med. 2022 Sep;11(17):3226-3237. doi: 10.1002/cam4.4686. Epub 2022 Mar 23.
3
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.一种用于检测肺癌中ALK、ROS1和RET融合的单管多重检测法。
J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.
4
Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.非腺癌非小细胞肺癌患者中 ALK、ROS1 和 RET 重排的临床病理特征和生存情况。
Cancer Biol Ther. 2017 Nov 2;18(11):883-887. doi: 10.1080/15384047.2016.1235660. Epub 2016 Sep 16.
5
Identification of , , and Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.通过多重 mRNA 检测方法在晚期非小细胞肺癌福尔马林固定石蜡包埋样本中鉴定 、 和 融合。
Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.
6
Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.多中心评估一种自动化、多重、基于 RNA 的分子检测方法,用于检测 NSCLC 中的 ALK、ROS1、RET 融合和 MET 外显子 14 跳跃。
Virchows Arch. 2024 Apr;484(4):677-686. doi: 10.1007/s00428-024-03778-9. Epub 2024 Mar 16.
7
ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.肺鳞状细胞癌中的ALK、ROS1和RET重排非常罕见。
Lung Cancer. 2016 Apr;94:22-7. doi: 10.1016/j.lungcan.2016.01.011. Epub 2016 Jan 21.
8
Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.采用下一代测序技术检测非小细胞肺癌患者的基因重排。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Jun;164(2):127-132. doi: 10.5507/bp.2020.015. Epub 2020 Apr 6.
9
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.ROS1 重排肺腺癌检测中检测算法的相关性。
Lung Cancer. 2014 Feb;83(2):168-73. doi: 10.1016/j.lungcan.2013.11.019. Epub 2013 Dec 1.
10
Novel targets in non-small cell lung cancer: ROS1 and RET fusions.非小细胞肺癌的新靶点:ROS1 和 RET 融合。
Oncologist. 2013;18(7):865-75. doi: 10.1634/theoncologist.2013-0095. Epub 2013 Jun 28.

引用本文的文献

1
Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib.抗肿瘤药物塞尔帕替尼相关物质及降解产物检测方法的研究
Front Chem. 2025 Jan 13;12:1534132. doi: 10.3389/fchem.2024.1534132. eCollection 2024.
2
Current status of molecular diagnostics for lung cancer.肺癌分子诊断的现状
Explor Target Antitumor Ther. 2024;5(3):742-765. doi: 10.37349/etat.2024.00244. Epub 2024 Jun 27.
3
Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with -mutated metastatic intrahepatic cholangiocarcinoma: a case report.

本文引用的文献

1
and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.MSI 状态在一大系列连续结直肠癌中的情况。
Int J Mol Sci. 2023 Mar 2;24(5):4868. doi: 10.3390/ijms24054868.
2
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.RET 融合阳性非小细胞肺癌:不断变化的治疗格局。
Oncologist. 2023 May 8;28(5):402-413. doi: 10.1093/oncolo/oyac264.
3
Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.RET 融合阳性晚期非小细胞肺癌的治疗:现状与展望。
一名患有KRAS突变型转移性肝内胆管癌的年轻女性对曲美替尼、羟氯喹和贝伐单抗的反应:病例报告
Explor Target Antitumor Ther. 2024;5(3):780-788. doi: 10.37349/etat.2024.00246. Epub 2024 Jun 28.
4
Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.盲目应用靶向抗癌药物:在炒作与谨慎之间寻求平衡。
Int J Mol Sci. 2024 Apr 7;25(7):4094. doi: 10.3390/ijms25074094.
5
Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.基于定制3' RACE的二代测序(NGS)检测板对胆道癌的分子分析
Diagnostics (Basel). 2023 Oct 10;13(20):3168. doi: 10.3390/diagnostics13203168.
6
Cost-Efficient Detection of Gene Fusions: Single-Center Analysis of 8075 Tumor Samples.经济高效的基因融合检测:8075 个肿瘤样本的单中心分析。
Int J Mol Sci. 2023 Sep 17;24(18):14203. doi: 10.3390/ijms241814203.
7
, , and Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers.结直肠癌及非结直肠微卫星不稳定型癌症中的基因融合。
Int J Mol Sci. 2023 Sep 2;24(17):13610. doi: 10.3390/ijms241713610.
Int J Mol Sci. 2023 Jan 26;24(3):2433. doi: 10.3390/ijms24032433.
4
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.RET-MAP 研究:一项关于携 RET 融合的肺癌患者临床生物学特征和治疗应答的国际多中心研究。
J Thorac Oncol. 2023 May;18(5):576-586. doi: 10.1016/j.jtho.2022.12.018. Epub 2023 Jan 13.
5
Clinicopathologic characteristics and diagnostic methods of rearrangement in Chinese non-small cell lung cancer patients.中国非小细胞肺癌患者重排的临床病理特征及诊断方法
Transl Lung Cancer Res. 2022 Apr;11(4):617-631. doi: 10.21037/tlcr-22-202.
6
Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.全面评估 5'-/3'-端 mRNA 不平衡表达检测作为肺癌中 ALK 和 ROS1 融合的筛查工具。
Cancer Med. 2022 Sep;11(17):3226-3237. doi: 10.1002/cam4.4686. Epub 2022 Mar 23.
7
The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.中国非小细胞肺癌(NSCLC)患者中 RET 融合阳性肿瘤的基因组特征。
J Cancer Res Clin Oncol. 2023 Mar;149(3):1019-1028. doi: 10.1007/s00432-022-03959-6. Epub 2022 Feb 26.
8
Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.用于预测肿瘤对细胞毒药物敏感性的分子检测。
Cancer Lett. 2022 Feb 1;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.
9
Catalog of 5' fusion partners in NSCLC Circa 2020.2020年前后非小细胞肺癌中5'融合伴侣目录
JTO Clin Res Rep. 2020 Mar 30;1(2):100037. doi: 10.1016/j.jtocrr.2020.100037. eCollection 2020 Jun.
10
Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization.分离荧光原位杂交检测 RET 融合的分析准确性。
Arch Pathol Lab Med. 2022 Mar 1;146(3):351-359. doi: 10.5858/arpa.2020-0376-OA.